Serum S100B protein concentrations in SGA/FGR newborns

Strzalko, Barbara; Karowicz-Bilińska, Agata; Wyka, Krystyna; Krajewski, Paweł; Kesiak, Marcin; Kociszewska-Najman, Bozena

doi:10.5603/gp.a2021.0119

Cited by 6 publications

(8 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Second, the ACS ≤7 days group had the lowest median gestational age at delivery and birth weight among the three groups. Early gestational age and low birth weight have been associated with high S100B levels 46,47 ; however, S100B levels were significantly lower in the ACS ≤7 days group than in the other groups. Nevertheless, further studies with larger populations are needed for subgroup analysis, especially at ≥35 weeks' gestation.…”

Section: Discussionmentioning

confidence: 92%

“…To evaluate cord S100B levels, we used multiple linear regression for multivariate analysis of quantitative variables. As S100B levels are influenced by gestational age at delivery and SGA, 46,47 we conducted multivariate analyses including these as covariates. Birth weight was excluded from the covariates because of its multicollinearity with the gestational age at delivery.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Antenatal corticosteroids‐to‐delivery interval associates cord blood S100B levels

Fuma

Kotani

Ushida

et al. 2023

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Aim: Antenatal corticosteroids (ACS) are recommended for women at risk of preterm birth before 34 weeks' gestation. However, adverse effects of ACS on the fetal brain have also been reported. The time interval from ACS administration to delivery (ACS-to-delivery interval) might alter the effect of ACS on the fetal brain. This study aimed to evaluate the effect of ACS-to-delivery interval on cord blood S100 calcium-binding protein B (S100B) levels as a biomarker of brain damage. Methods: Women who delivered between 2012 and 2020 at a tertiary medical center were divided into three groups according to ACS use and ACS-to-delivery interval, retrospectively: non-ACS, ACS ≤7 days, and ACS >7 days. Patients who did not complete the ACS regimen were excluded. The primary outcome was cord blood S100B levels. Results: Cord blood S100B levels were significantly lower in the ACS ≤7 days group than in the non-ACS and ACS >7 days groups. In the multiple regression analysis, birth ≤7 days after ACS showed a significant negative association with S100B level (p < 0.001). Conclusions: Reduced S100B levels were observed in infants born ≤7 days after ACS but not in infants born >7 days after ACS. These findings suggest the importance of ACS timing to optimize its effects on the fetal brain, although further studies are required to identify these mechanisms.

show abstract

Section: Discussionmentioning

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Antenatal corticosteroids‐to‐delivery interval associates cord blood S100B levels

Fuma

Kotani

Ushida

et al. 2023

J of Obstet and Gynaecol

View full text Add to dashboard Cite

show abstract

“…Differences in GA were observed between studies and groups within studies (online suppl. Table 1) [26,29,41,52,54,57,58]. For example, Yue et al [26] investigated a number of biomarkers of interest; however, the median GA for FGR and non-FGR neonates was significantly different (29.9 weeks and 27.3 weeks, respectively).…”

Section: Limitationsmentioning

confidence: 99%

Blood Biomarkers in the Fetally Growth Restricted and Small for Gestational Age Neonate: Associations with Brain Injury

Musco¹,

Beecher²,

Chand³

et al. 2023

Dev Neurosci

View full text Add to dashboard Cite

Fetal growth restriction (FGR) and small for gestational age (SGA) infants have increased risk of mortality and morbidity. Although both FGR and SGA infants have low birthweights for gestational age, a diagnosis of FGR also requires assessments of umbilical artery Doppler, physiological determinants, neonatal features of malnutrition, and in utero growth retardation. Both FGR and SGA are associated with adverse neurodevelopmental outcomes ranging from learning and behavioral difficulties to cerebral palsy. Up to 50% of FGR, newborns are not diagnosed until around the time of birth, yet this diagnosis lacks further indication of the risk of brain injury or adverse neurodevelopmental outcomes. Blood biomarkers may be a promising tool. Defining blood biomarkers indicating an infant’s risk of brain injury would provide the opportunity for early detection and therefore earlier support. The aim of this review was to summarize the current literature to assist in guiding the future direction for the early detection of adverse brain outcomes in FGR and SGA neonates. The studies investigated potential diagnostic blood biomarkers from cord and neonatal blood or serum from FGR and SGA human neonates. Results were often conflicting with heterogeneity common in the biomarkers examined, timepoints, gestational age, and definitions of FGR and SGA used. Due to these variations, it was difficult to draw strong conclusions from the results. The search for blood biomarkers of brain injury in FGR and SGA neonates should continue as early detection and intervention is critical to improve outcomes for these neonates.

show abstract

“…S100B is an acidic calcium-binding protein, which is mainly concentrated in the central nervous system and is associated with brain injury as a circulating biochemical marker caused by fetal chronic hypoxia in FGR and its levels are increased in FGR babies with intraventricular hemorrhage as revealed by testing in cord blood. [82][83][84][85] Yue et al 86 presented inflammatory markers, such as interleukin (IL) -6, IL-8, and IL-10, which are also related with FGR neonates with intraventricular hemorrhage and hypoxic ischemic encephalopathy. The other biochemical markers include adrenomedullin, activin A, neuronalspecific enolase (NSE), and glial fibrillary acid protein, related with ischemia reperfusion injury.…”

Section: Neurological Diseasementioning

confidence: 99%

Section: Potential Specific Biomarkers For Fetal Origins Of Adult Dis...mentioning

confidence: 99%

The Update of Fetal Growth Restriction Associated with Biomarkers

Sun¹

2022

Maternal-Fetal Medicine

View full text Add to dashboard Cite

Fetal growth restriction (FGR) has a prevalence of about 10% worldwide and is associated with an increased risk of perinatal mortality and morbidity. FGR is commonly caused by placental insufficiency and can begin early (<32 weeks) or in late (≥32 weeks) gestational age. A false positive antenatal diagnosis may lead to unnecessary monitoring and interventions, as well as cause maternal anxiety. Whereas a false negative diagnosis exposes the fetus to an increased risk of stillbirth and renders the pregnancy ineligible from the appropriate care and potential treatments. The clinical management of FGR pregnancies faces a complex challenge of deciding on the optimal timing of delivery as currently the main solution is to deliver the baby early, but iatrogenic preterm delivery of infants is associated with adverse short-and long-term outcomes. Early and accurate diagnosis of FGR could aid in better stratification of clinical management, and the development and implementation of treatment options, ultimately benefiting clinical care and potentially improving both short-and long-term health outcomes. The aim of this review is to present the new insights on biomarkers of placenta insufficiency, including their current and potential value of biomarkers in the prediction and prevention for FGR, and highlight the association between biomarkers and adverse outcomes in utero to explore the specific mechanism of impaired fetal growth that establish the basis for disease later in life.

show abstract

Serum S100B protein concentrations in SGA/FGR newborns

Cited by 6 publications

References 20 publications

Antenatal corticosteroids‐to‐delivery interval associates cord blood S100B levels

Antenatal corticosteroids‐to‐delivery interval associates cord blood S100B levels

Blood Biomarkers in the Fetally Growth Restricted and Small for Gestational Age Neonate: Associations with Brain Injury

The Update of Fetal Growth Restriction Associated with Biomarkers

Contact Info

Product

Resources

About